Benjamin Savage, DO
Internal Medicine · Chicago, ILNPI 1639515281
Payments from drug & device makers
Across 91 payments — averaging $252.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$16K
- Argenx US, Inc.$5K
- Livanova USA, Inc.$765
- Teva Pharmaceuticals USA, Inc.$117
- Novartis$91
- Pfizer$89
- plus $796 from 23 others
What the payments were for
- Consulting fees$3,56315%
- Speaking & faculty fees$15,28866%
- Travel & lodging$2,35810%
- Food & beverage$1,6987%
- Education$910%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 22 | $15,963 |
| Argenx US, Inc. | 10 | $5,177 |
| Livanova USA, Inc. | 7 | $765 |
| Teva Pharmaceuticals USA, Inc. | 2 | $117 |
| Novartis | 4 | $91 |
| Pfizer | 5 | $89 |
| Biohaven Pharmaceuticals, Inc. | 4 | $83 |
| AbbVie | 3 | $65 |
| Eisai Inc. | 3 | $58 |
| EMD Serono, Inc. | 3 | $57 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $42 |
| AstraZeneca | 3 | $42 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $41 |
| Tanabe Pharma America, Inc. | 2 | $40 |
| SK Life Science, Inc. | 2 | $39 |
| Acorda Therapeutics, Inc | 2 | $38 |
| Genentech USA, Inc. | 2 | $37 |
| UCB, Inc. | 1 | $28 |
| Johnson & Johnson | 1 | $28 |
| Merz Pharmaceuticals, LLC | 1 | $27 |
| Bio Products Laboratory USA, Inc. | 2 | $23 |
| TG Therapeutics, Inc. | 1 | $21 |
| Otsuka America Pharmaceutical, Inc. | 1 | $21 |
| Greenwich Biosciences, Inc. | 1 | $20 |
| Jazz Pharmaceuticals Inc. | 1 | $19 |
| Neurelis, Inc. | 1 | $18 |
| Amgen | 1 | $17 |
| Axsome Therapeutics, Inc. | 1 | $17 |
| GE HealthCare | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- KISUNLA$12,217
- VNS Therapy$649
How this compares
$22,999 in reported general payments places this provider in the 95th percentile of 5,182 internal medicine providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FirdapseAmifampridine Phosphate | 13 | $737,648 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 26 | $299,084 |
| Radicava OrsEdaravone | 22 | $291,819 |
| GammaplexImmun Glob G(Igg)/Gly/Iga 0-50 | 20 | $256,173 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 26 | $114,089 |
| BriviactBrivaracetam | 44 | $80,244 |
| Nurtec OdtRimegepant Sulfate | 30 | $52,272 |
| Levetiracetam | 444 | $18,314 |
| LyricaPregabalin | 13 | $15,178 |
| XcopriCenobamate | 13 | $14,052 |
| LamictalLamotrigine | 12 | $11,784 |
| Lamotrigine | 154 | $10,084 |
| Carbamazepine ErCarbamazepine | 33 | $8,132 |
| Pyridostigmine Bromide ErPyridostigmine Bromide | 18 | $7,417 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 141 | $5,707 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bio Products Laboratory USA, Inc.Gammaplex | $23 | $256,17320 claims |
| UCB, Inc.Briviact | $28 | $80,24444 claims |
| PfizerNurtec Odt, Lyrica | $89 | $67,45043 claims |
| SK Life Science, Inc.Xcopri | $39 | $14,05213 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,182 internal medicine providers in Illinois.
Other internal medicine in Chicago
- Dennis LevinsonChicago$25.3M
- Danny SugimotoChicago$4M
- Peter O DonnellChicago$3.9M
- Daniel CatenacciChicago$3.5M
- Patricia WalshChicago$2.1M
- Merle DiamondChicago$1.7M
- Mohammed KassemChicago$1.3M
- David BakerChicago$1M
- Azazuddin AhmedChicago$912K
- Daniel BergerChicago$861K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.